Replies to post #23069 on RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

I received this email from Mark Varney a few minutes ago in response to my question about a PIPE vs. a licensing deal. I also asked about the release of data from SGP's trials with a COR Ampakine in depression and ADHD. I also requested that he (Varney) try to be a little more forthcoming with shareholders thrugh a CC and other means. Here is the full text of the email:



Thanks for your email. I am happy to communicate to shareholders, and so please feel free to call me directly.

I cannot be too specific in answering your questions, since we have not publically disclosed much of this information. Furthermore, we are evaluating several different licensing scenarios, and predicting the success of these ahead of time would be foolish.



Regarding the Org compounds, we should be receiving an update in the next few months. However, bear in mind that we cannot disclose confidential information from Schering unless it is material to us, such as triggering a milestone payment.



Regarding a CC, we can think about putting this together. Thanks for your suggestion.



Regards,



Mark A. Varney, Ph.D



Bladerunner

(I'm not sure how important this observation is, but I specifically asked Varney about the possibility of a PIPE vs. a licensiong deal, and he responded by ONLY referring to a licensing deal. You can all debate about the significance of that.)

[Jads14]

Why is a PIPE necessarily quicker than a deal? If the deal is imminent, it requires the same signatures as a PIPE, no more or less.

Deal takes two sides to agree not only on value but what is included in deal. PIPE is solely $$$ and a company like R&R usually has venture capitalists in waiting especially for a deal like COR's where in all likelihood most if not all investors will be putting in less than 5M if the past history means anything.